On January 8, 2024, Paul Moore, the Chief Scientific Officer of Zymeworks Inc (NASDAQ:ZYME), sold 9,799 shares of the company's stock, according to a recent SEC Filing. Zymeworks Inc is a clinical-stage biopharmaceutical company that is dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer.
Over the past year, the insider has sold a total of 9,799 shares and has not made any purchases of the company's stock.
The insider transaction history for Zymeworks Inc shows a pattern of insider activity. In the past year, there have been 5 insider buys and 3 insider sells. The following image illustrates the recent trend in insider transactions:
On the valuation front, Zymeworks Inc's shares were trading at $10.79 on the day of the insider's recent transaction. The company has a market cap of $807.821 million. The price-earnings ratio stands at 3.71, which is below the industry median of 31.42 and above the company's historical median price-earnings ratio.
According to the GuruFocus Value chart, Zymeworks Inc has a price-to-GF-Value ratio of 0.73, indicating that the stock is considered Modestly Undervalued. The GF Value is an intrinsic value estimate that takes into account historical trading multiples, a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
Investors and analysts often monitor insider transactions as they can provide insights into a company's internal perspective on the stock's value. However, it is important to consider a wide range of factors when evaluating the implications of insider trades.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
